サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1645728

無血清培地・特殊培地の世界市場：製品別、用途別、エンドユーザー別 - 機会分析と産業予測、2024年～2033年

Serum Free and Specialty Media Market By Product, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 300 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
無血清培地・特殊培地の世界市場：製品別、用途別、エンドユーザー別 - 機会分析と産業予測、2024年～2033年
出版日: 2024年12月01日
発行: Allied Market Research
ページ情報: 英文 300 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

無血清培地・特殊培地市場は、2023年に23億米ドルとなり、2024年から2033年までのCAGRは11.6%を示し、2033年までには69億米ドルに達すると推定されています。

Serum Free and Specialty Media Market-IMG1

無血清培地・特殊培地は、研究室や製薬産業でさまざまな種類の細胞の増殖をサポートするために使用される細胞培養製剤です。この種の培地は、成長因子を供給するためのウシ胎児血清のような動物血清を含まず、代わりに化学的に合成された代替物で代用されます。無血清培地・特殊培地は、ワクチン開発、タンパク質・ウイルス生産、遺伝子治療に利用されています。

モノクローナル抗体やワクチンの需要増に対応するためのバイオ医薬品産業の開拓は、無血清培地・特殊培地への要求を急増させ、それゆえ市場の発展を増大させています。さらに、食品医薬品局のようないくつかの規制機関は、バイオ医薬品における動物由来製品の使用を排除することを強調しており、これが無血清培地・特殊培地市場を牽引しています。現在、市場の動向を牽引している注目すべき傾向は、3D細胞培養モデル用の培地開発です。3D細胞培養モデルは、細胞増殖のために生体内環境を模倣した制御された条件を必要とします。無血清培地・特殊培地は、各細胞培養の特殊な目的に対応するよう特別に調合されているため、3Dモデルの制御された環境要件に合致しています。

しかし、最適な細胞増殖のための無血清培地・特殊培地の正確な調合を達成することは、時間と複雑なプロセスを要するため、拡張性に課題があり、市場成長の妨げとなっています。それとは反対に、安全性と病気治療の有望な可能性から、医療分野での細胞療法の採用が増加しており、無血清培地・特殊培地市場に有利な機会をもたらすと期待されています。世界最大の生物医学図書館である国立医学図書館（National Library of Medicine）の総説によると、2023年第1四半期末までに世界中で承認された遺伝子・細胞・RNA療法は100種類を超え、約3,700種類の療法が臨床または前臨床開発段階にあります。培地は治療用細胞の増殖に最適化された汚染のない環境を提供するため、細胞治療法の増加とともに新たな道が開けると予測されています。

セグメント別レビュー

無血清培地・特殊培地市場は、製品タイプ、用途、エンドユーザー、地域に区分されます。製品タイプ別では、CHO培地、HEK培地、ハイブリドーマ培地、その他に分別されます。用途別では、バイオ医薬品製造、組織工学・再生医療、その他に分類されます。エンドユーザー別では、製薬・バイオ医薬品企業、研究・学術機関、その他に分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州地域）、アジア太平洋（日本、中国、インド、オーストラリア、韓国、その他アジア太平洋）、ラテンアメリカ、中東・アフリカ（ブラジル、中国、アフリカ、アラビア、その他南米地域）で分析されています。

主な調査結果

製品タイプ別では、CHO培地セグメントが2023年の市場を独占しました。

用途別では、バイオ医薬品生産セグメントが2023年の市場で最も高いシェアを占めました。

エンドユーザー別では、製薬・バイオテクノロジー企業セグメントが2023年の市場で注目すべきシェアを獲得しました。

地域別では、北米が2023年に最も高い収益を上げました。

世界の無血清培地・特殊培地市場で事業を展開する主な主要企業は、Thermo Fischer、Merck KGAA、Danaher Corporation（Cytiva）、Sartorius AG、Biotechne、Pan-Biotec、Corning、FUJIFILM Irvine Scientific.、Lonza、MP Biomedicalsです。これらの主要企業は、製品発売、事業拡大、地理的拡大、競争市場での足場固めのための投資など、さまざまな主要な発展戦略を採用しています。

利害関係者にとっての主なメリット

当レポートでは、2023年から2033年までの無血清培地・特殊培地市場分析の市場セグメント、現在の動向、推定動向、力学を定量的に分析し、一般的な無血清培地・特殊培地市場の機会を特定します。

市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。

ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるよう、バイヤーとサプライヤーの潜在力を明らかにします。

無血清培地・特殊培地市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。

各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。

市場企業のポジショニングはベンチマーキングを容易にし、市場企業の現在のポジションを明確に理解することができます。

本レポートには、地域および世界の無血清培地・特殊培地市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析が含まれています。

本レポートで可能なレポートカスタマイズ（追加費用とスケジュールがあります。）

  • 国、地域、世界レベルでの患者/疫学データ
  • 規制ガイドライン
  • クライアントの関心に応じた追加企業プロファイル
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡張リスト
  • 過去の市場データ
  • SWOT分析

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主要な調査結果
    • 主要な影響要因
    • 主要な投資機会
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
      • バイオ医薬品生産の増加
      • 特殊細胞培養技術の進歩
      • 個別化医療と細胞ベースの治療法の成長
    • 抑制要因
      • 厳しい規制要件と高コストの克服
    • 機会
      • アニマルフリー、持続可能、倫理的な研究手法へのシフト

第4章 無血清培地・特殊培地市場：製品別

  • 概要
  • CHO培地
  • HEK培地
  • ハイブリドーマ培地
  • その他

第5章 無血清培地・特殊培地市場：用途別

  • 概要
  • バイオ医薬品製造
  • 組織工学・再生医療
  • その他

第6章 無血清培地・特殊培地市場：エンドユーザー別

  • 概要
  • 製薬・バイオテクノロジー企業
  • 研究・学術機関
  • その他

第7章 無血清培地・特殊培地市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • その他
  • ラテンアメリカ、中東・アフリカ
    • ブラジル
    • サウジアラビア
    • 南アフリカ
    • その他

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2023年

第9章 企業プロファイル

  • Sartorius AG
  • Danaher Corporation
  • Fujifilm Holdings Corporation
  • Merck KGaA
  • Lonza
  • PAN-Biotech
  • Corning Incorporated
  • MP Biomedicals
  • Bio-Techne
  • Thermo Fisher Scientific Inc.
目次
Product Code: A197307

The serum free and specialty media market was valued at $2.3 billion in 2023 and is estimated to reach $6.9 billion by 2033, exhibiting a CAGR of 11.6% from 2024 to 2033.

Serum Free and Specialty Media Market - IMG1

A serum-free and specialty media is a cell culture formulation used in laboratories and pharmaceutical industries to support the growth of different types of cells. This type of media does not contain animal serum such as fetal bovine serum for the supply of growth factors; instead, it is replaced by chemically synthesized alternatives. Serum-free and specialty media is utilized in vaccine development, protein & virus production, and gene therapy.

Expansion of the biopharmaceutical industry to cater to increasing demand for monoclonal antibodies and vaccines has upsurged the requirement for serum-free and specialty media, hence augmenting the development of the market. In addition, several regulatory bodies such as the Food and Drug Administration are stressing the elimination of animal-based product usage in biopharmaceuticals, which is driving the serum-free and specialty media market. A notable trend acquiring traction in the market currently is the development of media for 3D cell culture models, which require controlled conditions that mimic the in-vivo environment for cell growth. The serum-free and specialty media aligns with the controlled environment requirement of the 3D model as its formulation is particularly created to serve the specialized purpose of each cell culture.

However, achieving the accurate formulation of serum-free and specialty media for optimal cell growth is a time-consuming, complex process that presents scalability challenges and hampers the market growth. On the contrary, rise in the adoption of cell therapies in the medicine sector due to their safety and promising potential for curing diseases is expected to present lucrative opportunities for the serum-free and specialty media market. As per a review article on the National Library of Medicine-the largest biomedical library globally-by the end of the first quarter of 2023, there were more than 100 different approved gene, cell, and RNA therapies across the globe and approximately 3,700 therapies were in the clinical or preclinical development stage. As the media provides an optimized and contamination-free environment for the growth of therapeutic cells, it is projected to witness novel avenues with increasing cell therapy procedures.

Segment Review

The serum-free and specialty media market is segmented into product type, application, end user, and region. By product type, the market is segregated into CHO media, HEK media, hybridoma media, and others. As per application, it is classified into biopharmaceutical production, tissue engineering & regenerative medicine, and others. According to end user, it is classified into pharmaceutical & biopharmaceutical companies, research & academic institutes, and others. Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Key Findings

By product type, the CHO media segment dominated the market in 2023.

As per application, the biopharmaceutical production segment held the highest share of the market in 2023.

According to end user, the pharmaceutical & biotechnology companies segment acquired a notable stake in the market in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

Major key players that operate in the global serum-free and specialty media market are Thermo Fischer, Merck KGAA, Danaher Corporation (Cytiva), Sartorius AG, Biotechne, Pan-Biotec, Corning, FUJIFILM Irvine Scientific., Lonza, and MP Biomedicals. These major players have adopted various key development strategies such as product launch, expansion, geographical expansion, and investment to strengthen their foothold in the competitive market.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the serum free and specialty media market analysis from 2023 to 2033 to identify the prevailing serum free and specialty media market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the serum free and specialty media market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global serum free and specialty media market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Product

  • CHO Media
  • HEK Media
  • Hybridoma Media
  • Others

By Application

  • Biopharmaceutical Production
  • Tissue Engineering and Regenerative Medicine
  • Others

By End User

  • Pharmaceutical and Biotechnology Companies
  • Research and Academic Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of Asia-Pacific

Key Market Players:

    • Corning Incorporated
    • MP Biomedicals
    • Fujifilm Holdings Corporation
    • Lonza
    • Merck KGaA
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • PAN-Biotech
    • Bio-Techne
    • Sartorius AG

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. High bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in Biopharmaceutical Production
      • 3.4.1.2. Advancements in Specialty Cell Culture Technology
      • 3.4.1.3. Growth In Personalized Medicine and Cell-Based Therapies
    • 3.4.2. Restraints
      • 3.4.2.1. Navigating Strict Regulatory Requirements and High Costs
    • 3.4.3. Opportunities
      • 3.4.3.1. The shift towards animal-free, sustainable, and ethical research practices

CHAPTER 4: SERUM FREE AND SPECIALTY MEDIA MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. CHO Media
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. HEK Media
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Hybridoma Media
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: SERUM FREE AND SPECIALTY MEDIA MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Biopharmaceutical Production
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Tissue Engineering and Regenerative Medicine
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: SERUM FREE AND SPECIALTY MEDIA MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Pharmaceutical and Biotechnology Companies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Research and Academic Institutes
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: SERUM FREE AND SPECIALTY MEDIA MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Product
    • 7.2.3. Market size and forecast, by Application
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Product
      • 7.2.5.1.2. Market size and forecast, by Application
      • 7.2.5.1.3. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Product
      • 7.2.5.2.2. Market size and forecast, by Application
      • 7.2.5.2.3. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Product
      • 7.2.5.3.2. Market size and forecast, by Application
      • 7.2.5.3.3. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Product
    • 7.3.3. Market size and forecast, by Application
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Product
      • 7.3.5.1.2. Market size and forecast, by Application
      • 7.3.5.1.3. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Product
      • 7.3.5.2.2. Market size and forecast, by Application
      • 7.3.5.2.3. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Product
      • 7.3.5.3.2. Market size and forecast, by Application
      • 7.3.5.3.3. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Product
      • 7.3.5.4.2. Market size and forecast, by Application
      • 7.3.5.4.3. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Product
      • 7.3.5.5.2. Market size and forecast, by Application
      • 7.3.5.5.3. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Product
      • 7.3.5.6.2. Market size and forecast, by Application
      • 7.3.5.6.3. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Product
    • 7.4.3. Market size and forecast, by Application
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Product
      • 7.4.5.1.2. Market size and forecast, by Application
      • 7.4.5.1.3. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Product
      • 7.4.5.2.2. Market size and forecast, by Application
      • 7.4.5.2.3. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Product
      • 7.4.5.3.2. Market size and forecast, by Application
      • 7.4.5.3.3. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Product
      • 7.4.5.4.2. Market size and forecast, by Application
      • 7.4.5.4.3. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Product
      • 7.4.5.5.2. Market size and forecast, by Application
      • 7.4.5.5.3. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Product
      • 7.4.5.6.2. Market size and forecast, by Application
      • 7.4.5.6.3. Market size and forecast, by End User
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Product
    • 7.5.3. Market size and forecast, by Application
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Product
      • 7.5.5.1.2. Market size and forecast, by Application
      • 7.5.5.1.3. Market size and forecast, by End User
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Product
      • 7.5.5.2.2. Market size and forecast, by Application
      • 7.5.5.2.3. Market size and forecast, by End User
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Market size and forecast, by Product
      • 7.5.5.3.2. Market size and forecast, by Application
      • 7.5.5.3.3. Market size and forecast, by End User
      • 7.5.5.4. Rest of Asia-Pacific
      • 7.5.5.4.1. Market size and forecast, by Product
      • 7.5.5.4.2. Market size and forecast, by Application
      • 7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Sartorius AG
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Danaher Corporation
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Fujifilm Holdings Corporation
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Merck KGaA
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Lonza
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. PAN-Biotech
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
  • 9.7. Corning Incorporated
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. MP Biomedicals
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
  • 9.9. Bio-Techne
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Thermo Fisher Scientific Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance